Oily Skin AgingNCT07310706
A Study to Evaluate the Efficacy of a Facial Sunscreen in Adult Participants With Oily Skin and Signs of Aging
A study testing Sunscreen A use in people with Oily Skin Aging, run by Kenvue Brands LLC at 1 site in Brazil.
Trial summary
This is a Single-Site, open-label, randomized clinical study that aims to evaluate the efficacy of the investigational product in improving the signs of skin aging and reducing facial oiliness in a population from 30 to 55 years of age. Read more about this study
- Who is it for?
- Ages 30 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Oily Skin Aging
- What is being tested?
- Sunscreen A use
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 73 participants
- Where
- 1 siteBrazil
- Study dates
- 21 Aug 2025to 26 Nov 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- For group I: 30 to 44 years of age; For group II: 45 to 55 years of age;
- Skin Type I to VI according to Fitzpatrick's classification. For each group:
- Fitzpatrick I and II: at least 8 participants II. Fitzpatrick III and IV: at least 8 participants III. Fitzpatrick V and VI: at least 8 participants
- Participants of any ethnicity according to IBGE criteria;
- Participants with oily or combination skin and oily shine on the face, both self-declared (through applied questionnaire) and confirmed by the dermatologist (from 2 points for oil shine by the modified Griffith scale from 0 to 9) at inclusion. For group I: oiliness will also be confirmed by Sebumeter (value above 100 AU for inclusion);
- Participants self-declared to have enlarged pores, confirmed by dermatologist;
Show all 14Show fewer
- Participants who show signs of mild to moderate aging (2 to 6 points for the parameters of wrinkles, fine lines, and skin roughness based on the modified Griffith scale of 0-9 points), confirmed by dermatologist at inclusion;
- Participant reports, at the time of inclusion, that he/she is concerned with at least one of the following parameters related to the appearance of facial skin:
- Fine lines II. Wrinkles III. Roughness/uneven texture
- Good general health, based on participant-reported medical history;
- Able to read, write, speak and understand Portuguese;
- For male participants: agree to shave 48 hours before study visits;
- Person who signed the ICF and ICIU;
- Intend to complete the study and are willing and able to follow all the instructions of the study.
Who cannot join
- Have known allergies or adverse reactions to common topical skin care products, including facial sunscreen;
- Have a skin condition that may influence the outcome of the study (specifically psoriasis, eczema, atopic dermatitis, cutaneous xerosis, erythema, or active skin cancer);
- Present primary/secondary lesions (e.g., scars, ulcers, vesicles, irritation resulting from the removal of facial hair) in the test areas;
- Report having Type 1 or Type 2 diabetes or taking insulin or other antidiabetic medication;
- Using medications that could mask an adverse event (AE) or influence the results of the study, including:
- Immunosuppressive or steroidal medications within 2 months prior to the first visit
Show all 20Show fewer
- Non-steroidal anti-inflammatory drugs within 5 days prior to the first visit
- Antihistamines within 2 weeks prior to the first visit
- Antibiotics (oral or topical), hormonal therapy (except hormonal contraception methods), insulin, inhaled steroids (except prescribed for temporary allergy relief) within 1 month prior to the first visit.
- Participants who have undergone invasive aesthetic or dermatological treatments in the test area (face) within 2 months prior to the first visit;
- Menopausal or postmenopausal women (except for perimenopausal women who are eligible for the study);
- Presence of excess hair in the evaluation area (face) that may interfere with instrumental evaluations. In the case of men, they will be instructed to shave 48 hours before visits;
- Use of any products that may interfere with study assessments, at the discretion of the dermatologist;
- Participants who have undergone chemical and/or physical peeling, laser, or similar aesthetic treatments within 6 months prior to the study;
- Participants who reported being pregnant, planning to become pregnant, or breastfeeding during the study;
- Have a history of or currently have a health condition/situation that could put the subject at significant risk, confound the results of the study, or significantly interfere with their participation in the study;
- Be simultaneously participating in another clinical study;
- Be an employee/contractor or close relative of the PI, Study Site or Sponsor;
- Participants who practice activities (leisure or work) with intense sun exposure;
- Smoking participants (Note: participants living with smokers may be eligible, provided that, at the discretion of the investigator, the participant's exposure to cigarettes does not interfere with or confound the results of the study. The participant's coexistence with a smoker must be reported as informative data).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Eight-Week, Single-Site Study to Evaluate the Efficacy of a Facial Sunscreen in Adult Participants With Oily Skin and Signs of Aging
This is a Single-Site, open-label, randomized clinical study that aims to evaluate the efficacy of the investigational product in improving the signs of skin aging and reducing facial oiliness in a population from 30 to 55 years of age.
- Conditions
- Oily Skin Aging
- Being tested
- Sunscreen A use
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sunscreen A useOther
The application of the Investigational Product will be performed by the participant and supervised by a qualified technician at Visit 1 and by the participant in their home.
Home use:
The Investigational Product will be applied topically by the participant, following the following mode of use:
"Apply an abundant amount (equivalent to one teaspoon) daily to the face and neck, at least twice a day, with reapplications whenever necessary."
| Study group | Role | What they receive |
|---|---|---|
| Group I: 30 to 44 years of age | Experimental | Group I: 30 participants in the age group of 30 to 44 years old, being:
* At least 8 with skin type I and II on the Fitzpatrick scale
* At least 8 with skin type III and IV on the Fitzpatrick scale
* At least 8 with skin type V and VI on the Fitzpatrick scale Receives: Other: Sunscreen A use |
| Group II: 45 to 55 years of age | Experimental | Group II: 30 participants in the age group of 45 to 55 years old, being:
* At least 8 with skin type I and II on the Fitzpatrick scale
* At least 8 with skin type III and IV on the Fitzpatrick scale
* At least 8 with skin type V and VI on the Fitzpatrick scale Receives: Other: Sunscreen A use |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical efficacy of the use of Investigational Product on signs of facial aging via dermatological evaluation
It is expected to obtain statistical improvement (p≤0.05) in the evaluated attributes such as reduction of wrinkles, fine lines and roughness of the skin through the dermatological clinical evaluation of wrinkles, fine lines, and skin roughness parameters using the modified 10-point Griffith scale (from 0 to 9).
Measured: Before and after Visit 1 (Day 0), Visit 2 (28 ± 2 days) and Visit 3 (56 ± 2 days ) of IP use
Clinical efficacy of Investigational Product in reducing skin oiliness via dermatological evaluation
It is expected to obtain statistical improvement (p≤0.05) in the evaluated attributes such as reduction of oiliness, reduction of oiliness shine, reduction of the appearance of pores through the dermatological clinical efficacy of oil shine using the modified 10-point Griffith scale (from 0 to 9).
Measured: Before and after Visit 1 (Day 0), Visit 2 (28 ± 2 days) and Visit 3 (56 ± 2 days ) of IP use
Clinical efficacy of Investigational Product in reducing pores
It is expected to obtain statistical improvement (p≤0.05) in the evaluated attributes such as reduction of the appearance of pores through the dermatological clinical efficacy of pore appearance via modified 10-point Griffith scale (from 0 to 9).
Measured: Before and after Visit 1 (Day 0) and Visit 3 (56 ± 2 days ) of IP use
Efficacy perceived by the participant through a questionnaire assessment
Efficacy measured by the participant through a questionnaire evaluating:
- clinical efficacy of the use of Investigational Product on signs of facial aging
- clinical efficacy of Investigational Product in reducing skin oiliness
- clinical efficacy of Investigational Product in reducing pores
Measured: Before and after Visit 1 (Day 0) and Visit 3 (56 ± 2 days ) of IP use
Clinical efficacy of the use of Investigational Product on signs of facial aging
Facial image captures using the COLORFACE equipment.
Measured: Before and after Visit 1 (Day 0) and Visit 3 (56 ± 2 days ) of IP use
Clinical efficacy of the use of Investigational Product on signs of facial aging via image analysis
It is expected to obtain statistical improvement (p≤0.05) in the evaluated equipment described below:
- Evaluation of the facial images by the ANTERA 3D equipment.
Measured: Before and after Visit 1 (Day 0), Visit 2 (28 ± 2 days) and Visit 3 (56 ± 2 days ) of IP use
Clinical efficacy of Investigational Product in reducing skin oiliness via instrumental measurements
It is expected to obtain statistical improvement (p≤0.05) in the evaluated attributes such as reduction of oiliness through the equipment below:
- Instrumental measurements with the Sebumeter® equipment.
Measured: Before and after Visit 1 (Day 0), Visit 2 (28 ± 2 days) and Visit 3 (56 ± 2 days ) of IP use
Secondary outcomes (2)
The clinical efficacy of Investigational Product in maintaining skin hydration
It is expected to obtain statistical improvement (p≤0.05) in the evaluated attributes, such as skin hydration through the equipment and evaluations described below:
- To evaluate the clinical efficacy of Investigational Product in maintaining skin hydration, by measurements with Corneometer® equipment.
Measured: Before and after Visit 1 (Day 0) and Visit 3 (56 ± 2 days ) of IP use
The clinical efficacy of Investigational Product in maintaining the skin barrier
It is expected to obtain statistical improvement (p≤0.05) in the evaluated attributes, such as reduction and/or maintenance of trans epidermal water loss through the equipment and evaluations described below:
- To evaluate the clinical efficacy of Investigational Product in maintaining trans epidermal water loss with Tewameter equipment.
Measured: Before and after Visit 1 (Day 0) and Visit 3 (56 ± 2 days ) of IP use
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Dec 2025
- Study start21 Aug 2025
- Primary completion16 Oct 2025
- Study completion26 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Oily Skin AgingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 73 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kenvue Brands LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07310706
- Sponsor's protocol ID
- CS2025SK100253
- Status last verified
- 18 Dec 2025
- First submitted
- 20 Nov 2025
- Last updated
- 30 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Eight-Week, Single-Site Study to Evaluate the Efficacy of a Facial Sunscreen in Adult Participants With Oily Skin and Signs of Aging
- ClinicalTrials.gov ID
- NCT07310706
- Acronym / sponsor ID
- CS2025SK100253
- Conditions
- Oily Skin Aging
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 73 participants (actual)
- Lead sponsor
- Kenvue Brands LLCIndustry (pharma, biotech, devices)
- Study start
- 21 Aug 2025 (actual)
- Primary completion
- 16 Oct 2025 (actual)
- Study completion
- 26 Nov 2025 (actual)
- First posted
- 30 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Single-Site, open-label, randomized clinical study that aims to evaluate the efficacy of the investigational product in improving the signs of skin aging and reducing facial oiliness in a population from 30 to 55 years of age.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group I: 30 to 44 years of age | Experimental | Other: Sunscreen A useGroup I: 30 participants in the age group of 30 to 44 years old, being: * At least 8 with skin type I and II on the Fitzpatrick scale * At least 8 with skin type III and IV on the Fitzpatrick scale * At least 8 with skin type V and VI on the Fitzpatrick scale |
| Group II: 45 to 55 years of age | Experimental | Other: Sunscreen A useGroup II: 30 participants in the age group of 45 to 55 years old, being: * At least 8 with skin type I and II on the Fitzpatrick scale * At least 8 with skin type III and IV on the Fitzpatrick scale * At least 8 with skin type V and VI on the Fitzpatrick scale |
Who may qualify
- Ages
- 30 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (14 listed)
- For group I: 30 to 44 years of age; For group II: 45 to 55 years of age;
- Skin Type I to VI according to Fitzpatrick's classification. For each group:
- Participants of any ethnicity according to IBGE criteria;
- Participants with oily or combination skin and oily shine on the face, both self-declared (through applied questionnaire) and confirmed by the dermatologist (from 2 points for oil shine by the modified Griffith scale from 0 to 9) at inclusion. For group I: oiliness will also be confirmed by Sebumeter (value above 100 AU for inclusion);
- Participants self-declared to have enlarged pores, confirmed by dermatologist;
Key exclusion criteria (20 listed)
- Have known allergies or adverse reactions to common topical skin care products, including facial sunscreen;
- Have a skin condition that may influence the outcome of the study (specifically psoriasis, eczema, atopic dermatitis, cutaneous xerosis, erythema, or active skin cancer);
- Present primary/secondary lesions (e.g., scars, ulcers, vesicles, irritation resulting from the removal of facial hair) in the test areas;
- Report having Type 1 or Type 2 diabetes or taking insulin or other antidiabetic medication;
- Using medications that could mask an adverse event (AE) or influence the results of the study, including:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sunscreen A useThe application of the Investigational Product will be performed by the participant and supervised by a qualified technician at Visit 1 and by the participant in their home. Home use: The Investigational Product will be applied topically by the participant, following the following mode of use: "Apply an abundant amount (equivalent to one teaspoon) daily to the face and neck, at least twice a day, with reapplications whenever necessary." | Other | Group I: 30 to 44 years of age, Group II: 45 to 55 years of age |
Primary outcome
Clinical efficacy of the use of Investigational Product on signs of facial aging via dermatological evaluation
Time frame: Before and after Visit 1 (Day 0), Visit 2 (28 ± 2 days) and Visit 3 (56 ± 2 days ) of IP use
It is expected to obtain statistical improvement (p≤0.05) in the evaluated attributes such as reduction of wrinkles, fine lines and roughness of the skin through the dermatological clinical evaluation of wrinkles, fine lines, and skin roughness parameters using the modified 10-point Griffith scale (from 0 to 9).
Clinical efficacy of Investigational Product in reducing skin oiliness via dermatological evaluation
Time frame: Before and after Visit 1 (Day 0), Visit 2 (28 ± 2 days) and Visit 3 (56 ± 2 days ) of IP use
It is expected to obtain statistical improvement (p≤0.05) in the evaluated attributes such as reduction of oiliness, reduction of oiliness shine, reduction of the appearance of pores through the dermatological clinical efficacy of oil shine using the modified 10-point Griffith scale (from 0 to 9).
Clinical efficacy of Investigational Product in reducing pores
Time frame: Before and after Visit 1 (Day 0) and Visit 3 (56 ± 2 days ) of IP use
It is expected to obtain statistical improvement (p≤0.05) in the evaluated attributes such as reduction of the appearance of pores through the dermatological clinical efficacy of pore appearance via modified 10-point Griffith scale (from 0 to 9).
Efficacy perceived by the participant through a questionnaire assessment
Time frame: Before and after Visit 1 (Day 0) and Visit 3 (56 ± 2 days ) of IP use
Efficacy measured by the participant through a questionnaire evaluating: * clinical efficacy of the use of Investigational Product on signs of facial aging * clinical efficacy of Investigational Product in reducing skin oiliness * clinical efficacy of Investigational Product in reducing pores
Clinical efficacy of the use of Investigational Product on signs of facial aging
Time frame: Before and after Visit 1 (Day 0) and Visit 3 (56 ± 2 days ) of IP use
Facial image captures using the COLORFACE equipment.
Clinical efficacy of the use of Investigational Product on signs of facial aging via image analysis
Time frame: Before and after Visit 1 (Day 0), Visit 2 (28 ± 2 days) and Visit 3 (56 ± 2 days ) of IP use
It is expected to obtain statistical improvement (p≤0.05) in the evaluated equipment described below: - Evaluation of the facial images by the ANTERA 3D equipment.
Clinical efficacy of Investigational Product in reducing skin oiliness via instrumental measurements
Time frame: Before and after Visit 1 (Day 0), Visit 2 (28 ± 2 days) and Visit 3 (56 ± 2 days ) of IP use
It is expected to obtain statistical improvement (p≤0.05) in the evaluated attributes such as reduction of oiliness through the equipment below: * Instrumental measurements with the Sebumeter® equipment.
2 secondary outcomes
The clinical efficacy of Investigational Product in maintaining skin hydration
Time frame: Before and after Visit 1 (Day 0) and Visit 3 (56 ± 2 days ) of IP use
The clinical efficacy of Investigational Product in maintaining the skin barrier
Time frame: Before and after Visit 1 (Day 0) and Visit 3 (56 ± 2 days ) of IP use
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Oily Skin Aging
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Sunscreen A use in people with Oily Skin Aging, run by Kenvue Brands LLC at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical efficacy of the use of Investigational Product on signs of facial aging via dermatological evaluation (time frame: Before and after Visit 1 (Day 0), Visit 2 (28 ± 2 days) and Visit 3 (56 ± 2 days ) of IP use). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Dec 2025.